Skip to main content

MedCloud Minute

Blog archive

Sartorius Launches Platform to Improve Cell Therapy Manufacturing Efficiency

Key Takeaways

  • Sartorius launches Eveo Cell Therapy Platform to streamline scalable cell therapy manufacturing.
  • Integrated closed system automates cell processing steps from modification to final formulation.
  • Platform improves consistency, reduces manual intervention, and supports biopharma production scale-up.

Sartorius, a biopharmaceutical laboratory, has introduced a next-generation platform, the Eveo Cell Therapy Platform, aimed at improving efficiency and scalability in cell therapy production. The platform is designed to integrate key steps in the manufacturing process, helping organizations manage complex workflows involved in developing and producing cell-based therapies. The system focuses on improving process consistency, reducing manual intervention and enabling better control over production environments.

The new platform integrates cell selection, activation, gene modification, expansion, wash and concentration as well as final formulation into a closed system using critical raw materials to bioreactors and separation technologies.

Cell therapy manufacturing presents unique challenges due to the complexity of handling living cells and the need for precise, repeatable processes. Sartorius said the new platform is intended to help biopharmaceutical companies standardize operations while supporting the transition from research to large-scale production. Demand for cell and gene therapies continues to grow as new treatments enter clinical and commercial stages. Sartorius aims to begin with order processing in September 2026, with the first deliveries of the Eveo Platform expected by 2027.

Posted by MedCloudInsider Editors on 03/18/2026